Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM28XTE)

Drug Name
2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one Drug Info
Synonyms
CHEMBL180336; 2-(furan-2-yl)-3-phenethylquinazolin-4-one; AC1LEB94; 2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one; Oprea1_070906; 2-(2-furyl)-3-(2-phenylethyl)-4(3H)-quinazolinone; ZINC49416; NPS-53574; BDBM50162542; STK674065; AKOS005593239; MCULE-4160039246; ST008066; J3.621.250K; 2-(2-furyl)-3-phenethyl-4(3H)-quinazolinone; AG-205/11559428; SR-01000416527; SR-01000416527-1; 2-(2-furyl)-3-(2-phenylethyl)-3-hydroquinazolin-4-one; 2-(furan-2-yl)-3-(2-phenylethyl)quinazolin-4(3H)-one; A1715/0073151
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
683379
TTD Drug ID
DM28XTE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Extracellular calcium-sensing receptor (CASR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [2]
Etelcalcetide DMHP9BL Secondary hyperparathyroidism 5A51.1 Approved [3]
ASP7991 DM3TN1A Hyperparathyroidism 5A51 Phase 2 [4]
MK-5442 DMHTIGU Osteoporosis FB83.0 Phase 2 [5]
ATF-936 DMWGKHZ Osteoporosis FB83.0 Phase 1 [6]
AXT-914 DM7ZU3B Osteoporosis FB83.0 Phase 1 [7]
R-568 DM5NWPD N. A. N. A. Discontinued in Phase 2 [8]
Ronacaleret DM10ZJP Osteoporosis FB83.0 Discontinued in Phase 2 [9]
NPS-2143 DMQPXLF Osteoporosis FB83.0 Discontinued in Phase 2 [10]
NPS-2390 DMMRY0Z Cerebrovascular ischaemia 8B1Z Preclinical [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular calcium-sensing receptor (CASR) TTBUYHA CASR_HUMAN Inhibitor [1]

References

1 Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg Med Chem Lett. 2005 May 16;15(10):2537-40.
2 Clinical pipeline report, company report or official report of Amgen (2009).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616)
5 Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93.
6 ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.
7 AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10.
8 Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther. 1999 Jan;65(1):40-9.
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10 Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. Biochim Biophys Acta. 2013 Oct;1832(10):1634-52.
11 The Extracellular Calcium-Sensing Receptor (CASR) Regulates Gonadotropins-Induced Meiotic Maturation of Porcine Oocytes.Biol Reprod.2015 Dec;93(6):131.